Global Poxviridae Infections Drug Market Growth 2022-2028

1.1 Market Introduction

1.2 Years Considered

1.3 Research Objectives

1.4 Market Research Methodology

1.5 Research Process and Data Source

1.6 Economic Indicators

1.7 Currency Considered

2 Executive Summary

2.1 World Market Overview

2.1.1 Global Poxviridae Infections Drug Annual Sales 2017-2028

2.1.2 World Current & Future Analysis for Poxviridae Infections Drug by Geographic Region, 2017, 2022 & 2028

2.1.3 World Current & Future Analysis for Poxviridae Infections Drug by Country/Region, 2017, 2022 & 2028

2.2 Poxviridae Infections Drug Segment by Type

2.2.1 CJ-40011

2.2.2 24a

2.2.3 BA-368

2.2.4 Others

2.3 Poxviridae Infections Drug Sales by Type

2.3.1 Global Poxviridae Infections Drug Sales Market Share by Type (2017-2022)

2.3.2 Global Poxviridae Infections Drug Revenue and Market Share by Type (2017-2022)

2.3.3 Global Poxviridae Infections Drug Sale Price by Type (2017-2022)

2.4 Poxviridae Infections Drug Segment by Application

2.4.1 Hospital

2.4.2 Clinic

2.4.3 Others

2.5 Poxviridae Infections Drug Sales by Application

2.5.1 Global Poxviridae Infections Drug Sale Market Share by Application (2017-2022)

2.5.2 Global Poxviridae Infections Drug Revenue and Market Share by Application (2017-2022)

2.5.3 Global Poxviridae Infections Drug Sale Price by Application (2017-2022)

3 Global Poxviridae Infections Drug by Company

3.1 Global Poxviridae Infections Drug Breakdown Data by Company

3.1.1 Global Poxviridae Infections Drug Annual Sales by Company (2020-2022)

3.1.2 Global Poxviridae Infections Drug Sales Market Share by Company (2020-2022)

3.2 Global Poxviridae Infections Drug Annual Revenue by Company (2020-2022)

3.2.1 Global Poxviridae Infections Drug Revenue by Company (2020-2022)

3.2.2 Global Poxviridae Infections Drug Revenue Market Share by Company (2020-2022)

3.3 Global Poxviridae Infections Drug Sale Price by Company

3.4 Key Manufacturers Poxviridae Infections Drug Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Poxviridae Infections Drug Product Location Distribution

3.4.2 Players Poxviridae Infections Drug Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 World Historic Review for Poxviridae Infections Drug by Geographic Region

4.1 World Historic Poxviridae Infections Drug Market Size by Geographic Region (2017-2022)

4.1.1 Global Poxviridae Infections Drug Annual Sales by Geographic Region (2017-2022)

4.1.2 Global Poxviridae Infections Drug Annual Revenue by Geographic Region

4.2 World Historic Poxviridae Infections Drug Market Size by Country/Region (2017-2022)

4.2.1 Global Poxviridae Infections Drug Annual Sales by Country/Region (2017-2022)

4.2.2 Global Poxviridae Infections Drug Annual Revenue by Country/Region

4.3 Americas Poxviridae Infections Drug Sales Growth

4.4 APAC Poxviridae Infections Drug Sales Growth

4.5 Europe Poxviridae Infections Drug Sales Growth

4.6 Middle East & Africa Poxviridae Infections Drug Sales Growth

5 Americas

5.1 Americas Poxviridae Infections Drug Sales by Country

5.1.1 Americas Poxviridae Infections Drug Sales by Country (2017-2022)

5.1.2 Americas Poxviridae Infections Drug Revenue by Country (2017-2022)

5.2 Americas Poxviridae Infections Drug Sales by Type

5.3 Americas Poxviridae Infections Drug Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Poxviridae Infections Drug Sales by Region

6.1.1 APAC Poxviridae Infections Drug Sales by Region (2017-2022)

6.1.2 APAC Poxviridae Infections Drug Revenue by Region (2017-2022)

6.2 APAC Poxviridae Infections Drug Sales by Type

6.3 APAC Poxviridae Infections Drug Sales by Application

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 Europe

7.1 Europe Poxviridae Infections Drug by Country

7.1.1 Europe Poxviridae Infections Drug Sales by Country (2017-2022)

7.1.2 Europe Poxviridae Infections Drug Revenue by Country (2017-2022)

7.2 Europe Poxviridae Infections Drug Sales by Type

7.3 Europe Poxviridae Infections Drug Sales by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 Middle East & Africa

8.1 Middle East & Africa Poxviridae Infections Drug by Country

8.1.1 Middle East & Africa Poxviridae Infections Drug Sales by Country (2017-2022)

8.1.2 Middle East & Africa Poxviridae Infections Drug Revenue by Country (2017-2022)

8.2 Middle East & Africa Poxviridae Infections Drug Sales by Type

8.3 Middle East & Africa Poxviridae Infections Drug Sales by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 Market Drivers, Challenges and Trends

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 Manufacturing Cost Structure Analysis

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Poxviridae Infections Drug

10.3 Manufacturing Process Analysis of Poxviridae Infections Drug

10.4 Industry Chain Structure of Poxviridae Infections Drug

11 Marketing, Distributors and Customer

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Poxviridae Infections Drug Distributors

11.3 Poxviridae Infections Drug Customer

12 World Forecast Review for Poxviridae Infections Drug by Geographic Region

12.1 Global Poxviridae Infections Drug Market Size Forecast by Region

12.1.1 Global Poxviridae Infections Drug Forecast by Region (2023-2028)

12.1.2 Global Poxviridae Infections Drug Annual Revenue Forecast by Region (2023-2028)

12.2 Americas Forecast by Country

12.3 APAC Forecast by Region

12.4 Europe Forecast by Country

12.5 Middle East & Africa Forecast by Country

12.6 Global Poxviridae Infections Drug Forecast by Type

12.7 Global Poxviridae Infections Drug Forecast by Application

13 Key Players Analysis

13.1 Bavarian Nordic A/S

13.1.1 Bavarian Nordic A/S Company Information

13.1.2 Bavarian Nordic A/S Poxviridae Infections Drug Product Offered

13.1.3 Bavarian Nordic A/S Poxviridae Infections Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.1.4 Bavarian Nordic A/S Main Business Overview

13.1.5 Bavarian Nordic A/S Latest Developments

13.2 BioFactura, Inc.

13.2.1 BioFactura, Inc. Company Information

13.2.2 BioFactura, Inc. Poxviridae Infections Drug Product Offered

13.2.3 BioFactura, Inc. Poxviridae Infections Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.2.4 BioFactura, Inc. Main Business Overview

13.2.5 BioFactura, Inc. Latest Developments

13.3 CEL-SCI Corporation

13.3.1 CEL-SCI Corporation Company Information

13.3.2 CEL-SCI Corporation Poxviridae Infections Drug Product Offered

13.3.3 CEL-SCI Corporation Poxviridae Infections Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.3.4 CEL-SCI Corporation Main Business Overview

13.3.5 CEL-SCI Corporation Latest Developments

13.4 Chimerix, Inc.

13.4.1 Chimerix, Inc. Company Information

13.4.2 Chimerix, Inc. Poxviridae Infections Drug Product Offered

13.4.3 Chimerix, Inc. Poxviridae Infections Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.4.4 Chimerix, Inc. Main Business Overview

13.4.5 Chimerix, Inc. Latest Developments

13.5 China Biologic Products, Inc.

13.5.1 China Biologic Products, Inc. Company Information

13.5.2 China Biologic Products, Inc. Poxviridae Infections Drug Product Offered

13.5.3 China Biologic Products, Inc. Poxviridae Infections Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.5.4 China Biologic Products, Inc. Main Business Overview

13.5.5 China Biologic Products, Inc. Latest Developments

13.6 CJ HealthCare Corp.

13.6.1 CJ HealthCare Corp. Company Information

13.6.2 CJ HealthCare Corp. Poxviridae Infections Drug Product Offered

13.6.3 CJ HealthCare Corp. Poxviridae Infections Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.6.4 CJ HealthCare Corp. Main Business Overview

13.6.5 CJ HealthCare Corp. Latest Developments

13.7 EpiVax, Inc.

13.7.1 EpiVax, Inc. Company Information

13.7.2 EpiVax, Inc. Poxviridae Infections Drug Product Offered

13.7.3 EpiVax, Inc. Poxviridae Infections Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.7.4 EpiVax, Inc. Main Business Overview

13.7.5 EpiVax, Inc. Latest Developments

13.8 N & N Pharmaceuticals Inc.

13.8.1 N & N Pharmaceuticals Inc. Company Information

13.8.2 N & N Pharmaceuticals Inc. Poxviridae Infections Drug Product Offered

13.8.3 N & N Pharmaceuticals Inc. Poxviridae Infections Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.8.4 N & N Pharmaceuticals Inc. Main Business Overview

13.8.5 N & N Pharmaceuticals Inc. Latest Developments

13.9 SIGA Technologies, Inc.

13.9.1 SIGA Technologies, Inc. Company Information

13.9.2 SIGA Technologies, Inc. Poxviridae Infections Drug Product Offered

13.9.3 SIGA Technologies, Inc. Poxviridae Infections Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.9.4 SIGA Technologies, Inc. Main Business Overview

13.9.5 SIGA Technologies, Inc. Latest Developments

13.10 Takeda Pharmaceutical Company Limited

13.10.1 Takeda Pharmaceutical Company Limited Company Information

13.10.2 Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Product Offered

13.10.3 Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.10.4 Takeda Pharmaceutical Company Limited Main Business Overview

13.10.5 Takeda Pharmaceutical Company Limited Latest Developments

13.11 Tonix Pharmaceuticals Holding Corp.

13.11.1 Tonix Pharmaceuticals Holding Corp. Company Information

13.11.2 Tonix Pharmaceuticals Holding Corp. Poxviridae Infections Drug Product Offered

13.11.3 Tonix Pharmaceuticals Holding Corp. Poxviridae Infections Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.11.4 Tonix Pharmaceuticals Holding Corp. Main Business Overview

13.11.5 Tonix Pharmaceuticals Holding Corp. Latest Developments

13.12 Verrica Pharmaceuticals Inc.

13.12.1 Verrica Pharmaceuticals Inc. Company Information

13.12.2 Verrica Pharmaceuticals Inc. Poxviridae Infections Drug Product Offered

13.12.3 Verrica Pharmaceuticals Inc. Poxviridae Infections Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.12.4 Verrica Pharmaceuticals Inc. Main Business Overview

13.12.5 Verrica Pharmaceuticals Inc. Latest Developments

14 Research Findings and Conclusion

Table 1. Poxviridae Infections Drug Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)

Table 2. Poxviridae Infections Drug Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)

Table 3. Major Players of CJ-40011

Table 4. Major Players of 24a

Table 5. Major Players of BA-368

Table 6. Major Players of Others

Table 7. Global Poxviridae Infections Drug Sales by Type (2017-2022) & (K Pcs)

Table 8. Global Poxviridae Infections Drug Sales Market Share by Type (2017-2022)

Table 9. Global Poxviridae Infections Drug Revenue by Type (2017-2022) & ($ million)

Table 10. Global Poxviridae Infections Drug Revenue Market Share by Type (2017-2022)

Table 11. Global Poxviridae Infections Drug Sale Price by Type (2017-2022) & (USD/Pcs)

Table 12. Global Poxviridae Infections Drug Sales by Application (2017-2022) & (K Pcs)

Table 13. Global Poxviridae Infections Drug Sales Market Share by Application (2017-2022)

Table 14. Global Poxviridae Infections Drug Revenue by Application (2017-2022)

Table 15. Global Poxviridae Infections Drug Revenue Market Share by Application (2017-2022)

Table 16. Global Poxviridae Infections Drug Sale Price by Application (2017-2022) & (USD/Pcs)

Table 17. Global Poxviridae Infections Drug Sales by Company (2020-2022) & (K Pcs)

Table 18. Global Poxviridae Infections Drug Sales Market Share by Company (2020-2022)

Table 19. Global Poxviridae Infections Drug Revenue by Company (2020-2022) ($ Millions)

Table 20. Global Poxviridae Infections Drug Revenue Market Share by Company (2020-2022)

Table 21. Global Poxviridae Infections Drug Sale Price by Company (2020-2022) & (USD/Pcs)

Table 22. Key Manufacturers Poxviridae Infections Drug Producing Area Distribution and Sales Area

Table 23. Players Poxviridae Infections Drug Products Offered

Table 24. Poxviridae Infections Drug Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

Table 25. New Products and Potential Entrants

Table 26. Mergers & Acquisitions, Expansion

Table 27. Global Poxviridae Infections Drug Sales by Geographic Region (2017-2022) & (K Pcs)

Table 28. Global Poxviridae Infections Drug Sales Market Share Geographic Region (2017-2022)

Table 29. Global Poxviridae Infections Drug Revenue by Geographic Region (2017-2022) & ($ millions)

Table 30. Global Poxviridae Infections Drug Revenue Market Share by Geographic Region (2017-2022)

Table 31. Global Poxviridae Infections Drug Sales by Country/Region (2017-2022) & (K Pcs)

Table 32. Global Poxviridae Infections Drug Sales Market Share by Country/Region (2017-2022)

Table 33. Global Poxviridae Infections Drug Revenue by Country/Region (2017-2022) & ($ millions)

Table 34. Global Poxviridae Infections Drug Revenue Market Share by Country/Region (2017-2022)

Table 35. Americas Poxviridae Infections Drug Sales by Country (2017-2022) & (K Pcs)

Table 36. Americas Poxviridae Infections Drug Sales Market Share by Country (2017-2022)

Table 37. Americas Poxviridae Infections Drug Revenue by Country (2017-2022) & ($ Millions)

Table 38. Americas Poxviridae Infections Drug Revenue Market Share by Country (2017-2022)

Table 39. Americas Poxviridae Infections Drug Sales by Type (2017-2022) & (K Pcs)

Table 40. Americas Poxviridae Infections Drug Sales Market Share by Type (2017-2022)

Table 41. Americas Poxviridae Infections Drug Sales by Application (2017-2022) & (K Pcs)

Table 42. Americas Poxviridae Infections Drug Sales Market Share by Application (2017-2022)

Table 43. APAC Poxviridae Infections Drug Sales by Region (2017-2022) & (K Pcs)

Table 44. APAC Poxviridae Infections Drug Sales Market Share by Region (2017-2022)

Table 45. APAC Poxviridae Infections Drug Revenue by Region (2017-2022) & ($ Millions)

Table 46. APAC Poxviridae Infections Drug Revenue Market Share by Region (2017-2022)

Table 47. APAC Poxviridae Infections Drug Sales by Type (2017-2022) & (K Pcs)

Table 48. APAC Poxviridae Infections Drug Sales Market Share by Type (2017-2022)

Table 49. APAC Poxviridae Infections Drug Sales by Application (2017-2022) & (K Pcs)

Table 50. APAC Poxviridae Infections Drug Sales Market Share by Application (2017-2022)

Table 51. Europe Poxviridae Infections Drug Sales by Country (2017-2022) & (K Pcs)

Table 52. Europe Poxviridae Infections Drug Sales Market Share by Country (2017-2022)

Table 53. Europe Poxviridae Infections Drug Revenue by Country (2017-2022) & ($ Millions)

Table 54. Europe Poxviridae Infections Drug Revenue Market Share by Country (2017-2022)

Table 55. Europe Poxviridae Infections Drug Sales by Type (2017-2022) & (K Pcs)

Table 56. Europe Poxviridae Infections Drug Sales Market Share by Type (2017-2022)

Table 57. Europe Poxviridae Infections Drug Sales by Application (2017-2022) & (K Pcs)

Table 58. Europe Poxviridae Infections Drug Sales Market Share by Application (2017-2022)

Table 59. Middle East & Africa Poxviridae Infections Drug Sales by Country (2017-2022) & (K Pcs)

Table 60. Middle East & Africa Poxviridae Infections Drug Sales Market Share by Country (2017-2022)

Table 61. Middle East & Africa Poxviridae Infections Drug Revenue by Country (2017-2022) & ($ Millions)

Table 62. Middle East & Africa Poxviridae Infections Drug Revenue Market Share by Country (2017-2022)

Table 63. Middle East & Africa Poxviridae Infections Drug Sales by Type (2017-2022) & (K Pcs)

Table 64. Middle East & Africa Poxviridae Infections Drug Sales Market Share by Type (2017-2022)

Table 65. Middle East & Africa Poxviridae Infections Drug Sales by Application (2017-2022) & (K Pcs)

Table 66. Middle East & Africa Poxviridae Infections Drug Sales Market Share by Application (2017-2022)

Table 67. Key Market Drivers & Growth Opportunities of Poxviridae Infections Drug

Table 68. Key Market Challenges & Risks of Poxviridae Infections Drug

Table 69. Key Industry Trends of Poxviridae Infections Drug

Table 70. Poxviridae Infections Drug Raw Material

Table 71. Key Suppliers of Raw Materials

Table 72. Poxviridae Infections Drug Distributors List

Table 73. Poxviridae Infections Drug Customer List

Table 74. Global Poxviridae Infections Drug Sales Forecast by Region (2023-2028) & (K Pcs)

Table 75. Global Poxviridae Infections Drug Sales Market Forecast by Region

Table 76. Global Poxviridae Infections Drug Revenue Forecast by Region (2023-2028) & ($ millions)

Table 77. Global Poxviridae Infections Drug Revenue Market Share Forecast by Region (2023-2028)

Table 78. Americas Poxviridae Infections Drug Sales Forecast by Country (2023-2028) & (K Pcs)

Table 79. Americas Poxviridae Infections Drug Revenue Forecast by Country (2023-2028) & ($ millions)

Table 80. APAC Poxviridae Infections Drug Sales Forecast by Region (2023-2028) & (K Pcs)

Table 81. APAC Poxviridae Infections Drug Revenue Forecast by Region (2023-2028) & ($ millions)

Table 82. Europe Poxviridae Infections Drug Sales Forecast by Country (2023-2028) & (K Pcs)

Table 83. Europe Poxviridae Infections Drug Revenue Forecast by Country (2023-2028) & ($ millions)

Table 84. Middle East & Africa Poxviridae Infections Drug Sales Forecast by Country (2023-2028) & (K Pcs)

Table 85. Middle East & Africa Poxviridae Infections Drug Revenue Forecast by Country (2023-2028) & ($ millions)

Table 86. Global Poxviridae Infections Drug Sales Forecast by Type (2023-2028) & (K Pcs)

Table 87. Global Poxviridae Infections Drug Sales Market Share Forecast by Type (2023-2028)

Table 88. Global Poxviridae Infections Drug Revenue Forecast by Type (2023-2028) & ($ Millions)

Table 89. Global Poxviridae Infections Drug Revenue Market Share Forecast by Type (2023-2028)

Table 90. Global Poxviridae Infections Drug Sales Forecast by Application (2023-2028) & (K Pcs)

Table 91. Global Poxviridae Infections Drug Sales Market Share Forecast by Application (2023-2028)

Table 92. Global Poxviridae Infections Drug Revenue Forecast by Application (2023-2028) & ($ Millions)

Table 93. Global Poxviridae Infections Drug Revenue Market Share Forecast by Application (2023-2028)

Table 94. Bavarian Nordic A/S Basic Information, Poxviridae Infections Drug Manufacturing Base, Sales Area and Its Competitors

Table 95. Bavarian Nordic A/S Poxviridae Infections Drug Product Offered

Table 96. Bavarian Nordic A/S Poxviridae Infections Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 97. Bavarian Nordic A/S Main Business

Table 98. Bavarian Nordic A/S Latest Developments

Table 99. BioFactura, Inc. Basic Information, Poxviridae Infections Drug Manufacturing Base, Sales Area and Its Competitors

Table 100. BioFactura, Inc. Poxviridae Infections Drug Product Offered

Table 101. BioFactura, Inc. Poxviridae Infections Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 102. BioFactura, Inc. Main Business

Table 103. BioFactura, Inc. Latest Developments

Table 104. CEL-SCI Corporation Basic Information, Poxviridae Infections Drug Manufacturing Base, Sales Area and Its Competitors

Table 105. CEL-SCI Corporation Poxviridae Infections Drug Product Offered

Table 106. CEL-SCI Corporation Poxviridae Infections Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 107. CEL-SCI Corporation Main Business

Table 108. CEL-SCI Corporation Latest Developments

Table 109. Chimerix, Inc. Basic Information, Poxviridae Infections Drug Manufacturing Base, Sales Area and Its Competitors

Table 110. Chimerix, Inc. Poxviridae Infections Drug Product Offered

Table 111. Chimerix, Inc. Poxviridae Infections Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 112. Chimerix, Inc. Main Business

Table 113. Chimerix, Inc. Latest Developments

Table 114. China Biologic Products, Inc. Basic Information, Poxviridae Infections Drug Manufacturing Base, Sales Area and Its Competitors

Table 115. China Biologic Products, Inc. Poxviridae Infections Drug Product Offered

Table 116. China Biologic Products, Inc. Poxviridae Infections Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 117. China Biologic Products, Inc. Main Business

Table 118. China Biologic Products, Inc. Latest Developments

Table 119. CJ HealthCare Corp. Basic Information, Poxviridae Infections Drug Manufacturing Base, Sales Area and Its Competitors

Table 120. CJ HealthCare Corp. Poxviridae Infections Drug Product Offered

Table 121. CJ HealthCare Corp. Poxviridae Infections Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 122. CJ HealthCare Corp. Main Business

Table 123. CJ HealthCare Corp. Latest Developments

Table 124. EpiVax, Inc. Basic Information, Poxviridae Infections Drug Manufacturing Base, Sales Area and Its Competitors

Table 125. EpiVax, Inc. Poxviridae Infections Drug Product Offered

Table 126. EpiVax, Inc. Poxviridae Infections Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 127. EpiVax, Inc. Main Business

Table 128. EpiVax, Inc. Latest Developments

Table 129. N & N Pharmaceuticals Inc. Basic Information, Poxviridae Infections Drug Manufacturing Base, Sales Area and Its Competitors

Table 130. N & N Pharmaceuticals Inc. Poxviridae Infections Drug Product Offered

Table 131. N & N Pharmaceuticals Inc. Poxviridae Infections Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 132. N & N Pharmaceuticals Inc. Main Business

Table 133. N & N Pharmaceuticals Inc. Latest Developments

Table 134. SIGA Technologies, Inc. Basic Information, Poxviridae Infections Drug Manufacturing Base, Sales Area and Its Competitors

Table 135. SIGA Technologies, Inc. Poxviridae Infections Drug Product Offered

Table 136. SIGA Technologies, Inc. Poxviridae Infections Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 137. SIGA Technologies, Inc. Main Business

Table 138. SIGA Technologies, Inc. Latest Developments

Table 139. Takeda Pharmaceutical Company Limited Basic Information, Poxviridae Infections Drug Manufacturing Base, Sales Area and Its Competitors

Table 140. Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Product Offered

Table 141. Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 142. Takeda Pharmaceutical Company Limited Main Business

Table 143. Takeda Pharmaceutical Company Limited Latest Developments

Table 144. Tonix Pharmaceuticals Holding Corp. Basic Information, Poxviridae Infections Drug Manufacturing Base, Sales Area and Its Competitors

Table 145. Tonix Pharmaceuticals Holding Corp. Poxviridae Infections Drug Product Offered

Table 146. Tonix Pharmaceuticals Holding Corp. Poxviridae Infections Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 147. Tonix Pharmaceuticals Holding Corp. Main Business

Table 148. Tonix Pharmaceuticals Holding Corp. Latest Developments

Table 149. Verrica Pharmaceuticals Inc. Basic Information, Poxviridae Infections Drug Manufacturing Base, Sales Area and Its Competitors

Table 150. Verrica Pharmaceuticals Inc. Poxviridae Infections Drug Product Offered

Table 151. Verrica Pharmaceuticals Inc. Poxviridae Infections Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 152. Verrica Pharmaceuticals Inc. Main Business

Table 153. Verrica Pharmaceuticals Inc. Latest Developments

List of Figures

Figure 1. Picture of Poxviridae Infections Drug

Figure 2. Poxviridae Infections Drug Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global Poxviridae Infections Drug Sales Growth Rate 2017-2028 (K Pcs)

Figure 7. Global Poxviridae Infections Drug Revenue Growth Rate 2017-2028 ($ Millions)

Figure 8. Poxviridae Infections Drug Sales by Region (2021 & 2028) & ($ millions)

Figure 9. Product Picture of CJ-40011

Figure 10. Product Picture of 24a

Figure 11. Product Picture of BA-368

Figure 12. Product Picture of Others

Figure 13. Global Poxviridae Infections Drug Sales Market Share by Type in 2021

Figure 14. Global Poxviridae Infections Drug Revenue Market Share by Type (2017-2022)

Figure 15. Poxviridae Infections Drug Consumed in Hospital

Figure 16. Global Poxviridae Infections Drug Market: Hospital (2017-2022) & (K Pcs)

Figure 17. Poxviridae Infections Drug Consumed in Clinic

Figure 18. Global Poxviridae Infections Drug Market: Clinic (2017-2022) & (K Pcs)

Figure 19. Poxviridae Infections Drug Consumed in Others

Figure 20. Global Poxviridae Infections Drug Market: Others (2017-2022) & (K Pcs)

Figure 21. Global Poxviridae Infections Drug Sales Market Share by Application (2017-2022)

Figure 22. Global Poxviridae Infections Drug Revenue Market Share by Application in 2021

Figure 23. Poxviridae Infections Drug Revenue Market by Company in 2021 ($ Million)

Figure 24. Global Poxviridae Infections Drug Revenue Market Share by Company in 2021

Figure 25. Global Poxviridae Infections Drug Sales Market Share by Geographic Region (2017-2022)

Figure 26. Global Poxviridae Infections Drug Revenue Market Share by Geographic Region in 2021

Figure 27. Global Poxviridae Infections Drug Sales Market Share by Region (2017-2022)

Figure 28. Global Poxviridae Infections Drug Revenue Market Share by Country/Region in 2021

Figure 29. Americas Poxviridae Infections Drug Sales 2017-2022 (K Pcs)

Figure 30. Americas Poxviridae Infections Drug Revenue 2017-2022 ($ Millions)

Figure 31. APAC Poxviridae Infections Drug Sales 2017-2022 (K Pcs)

Figure 32. APAC Poxviridae Infections Drug Revenue 2017-2022 ($ Millions)

Figure 33. Europe Poxviridae Infections Drug Sales 2017-2022 (K Pcs)

Figure 34. Europe Poxviridae Infections Drug Revenue 2017-2022 ($ Millions)

Figure 35. Middle East & Africa Poxviridae Infections Drug Sales 2017-2022 (K Pcs)

Figure 36. Middle East & Africa Poxviridae Infections Drug Revenue 2017-2022 ($ Millions)

Figure 37. Americas Poxviridae Infections Drug Sales Market Share by Country in 2021

Figure 38. Americas Poxviridae Infections Drug Revenue Market Share by Country in 2021

Figure 39. United States Poxviridae Infections Drug Revenue Growth 2017-2022 ($ Millions)

Figure 40. Canada Poxviridae Infections Drug Revenue Growth 2017-2022 ($ Millions)

Figure 41. Mexico Poxviridae Infections Drug Revenue Growth 2017-2022 ($ Millions)

Figure 42. Brazil Poxviridae Infections Drug Revenue Growth 2017-2022 ($ Millions)

Figure 43. APAC Poxviridae Infections Drug Sales Market Share by Region in 2021

Figure 44. APAC Poxviridae Infections Drug Revenue Market Share by Regions in 2021

Figure 45. China Poxviridae Infections Drug Revenue Growth 2017-2022 ($ Millions)

Figure 46. Japan Poxviridae Infections Drug Revenue Growth 2017-2022 ($ Millions)

Figure 47. South Korea Poxviridae Infections Drug Revenue Growth 2017-2022 ($ Millions)

Figure 48. Southeast Asia Poxviridae Infections Drug Revenue Growth 2017-2022 ($ Millions)

Figure 49. India Poxviridae Infections Drug Revenue Growth 2017-2022 ($ Millions)

Figure 50. Australia Poxviridae Infections Drug Revenue Growth 2017-2022 ($ Millions)

Figure 51. Europe Poxviridae Infections Drug Sales Market Share by Country in 2021

Figure 52. Europe Poxviridae Infections Drug Revenue Market Share by Country in 2021

Figure 53. Germany Poxviridae Infections Drug Revenue Growth 2017-2022 ($ Millions)

Figure 54. France Poxviridae Infections Drug Revenue Growth 2017-2022 ($ Millions)

Figure 55. UK Poxviridae Infections Drug Revenue Growth 2017-2022 ($ Millions)

Figure 56. Italy Poxviridae Infections Drug Revenue Growth 2017-2022 ($ Millions)

Figure 57. Russia Poxviridae Infections Drug Revenue Growth 2017-2022 ($ Millions)

Figure 58. Middle East & Africa Poxviridae Infections Drug Sales Market Share by Country in 2021

Figure 59. Middle East & Africa Poxviridae Infections Drug Revenue Market Share by Country in 2021

Figure 60. Egypt Poxviridae Infections Drug Revenue Growth 2017-2022 ($ Millions)

Figure 61. South Africa Poxviridae Infections Drug Revenue Growth 2017-2022 ($ Millions)

Figure 62. Israel Poxviridae Infections Drug Revenue Growth 2017-2022 ($ Millions)

Figure 63. Turkey Poxviridae Infections Drug Revenue Growth 2017-2022 ($ Millions)

Figure 64. GCC Country Poxviridae Infections Drug Revenue Growth 2017-2022 ($ Millions)

Figure 65. Manufacturing Cost Structure Analysis of Poxviridae Infections Drug in 2021

Figure 66. Manufacturing Process Analysis of Poxviridae Infections Drug

Figure 67. Industry Chain Structure of Poxviridae Infections Drug

Figure 68. Channels of Distribution

Figure 69. Distributors Profiles